KPV (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Dosing is daily inside a course rather than open ended: 4 to 8 weeks on, then 2 to 4 weeks off, extended to 12 weeks for chronic IBD. The oral route is preferred for gut conditions because PepT1 is upregulated in inflamed intestinal tissue, so inflamed mucosa preferentially absorbs KPV; oral KPV also reaches gut tissue first, and systemic bioavailability is lower without a prodrug formulation. The subcutaneous route is preferred for systemic targets such as skin inflammation, joint inflammation, and post-procedure inflammation control, injected into subcutaneous tissue with sites rotated across abdomen, thighs, and upper arms. At 10 mg/mL a 500 mcg dose is only 5 units, so a syringe marked to 30 or 50 units reads more accurately than a full 100 unit barrel. The peptide is rapidly metabolized to its constituent amino acids, and because the mechanism is receptor independent there is no receptor to desensitize, so no tolerance or tachyphylaxis develops. NF-kB suppression begins in cell culture within about 66 minutes, at half-max IkB-alpha stabilization, and peaks by 2 hours; clinical timelines in humans are unknown.

Results Timeline

Sequence described in the research record. Individual response varies.

• About 66 minutes in cell culture: half-max IkB-alpha stabilization, the first measurable sign of NF-kB suppression.
• About 2 hours in cell culture: NF-kB suppression peaks.
• By 5 hours: histidine tagged KPV becomes exclusively nuclear in tracking studies.
• Days to weeks: disease activity improvements in animal colitis models.
• Human timeline: unknown. No clinical trial has measured onset, peak, or duration in people.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 200 mcg = 2 units, 500 mcg = 5 units, 1000 mcg = 10 units (0.10 mL), 1500 mcg = 15 units (0.15 mL).
5. For oral use, the same volume is drawn from the vial and administered sublingually or swallowed.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• A 10 mg vial at 10 mg/mL holds 1.0 mL, about 100 units, so a 500 mcg daily subcutaneous dose empties one vial in 20 days; reconstitute vials as the course needs them rather than opening several at once.

Supplies Needed

Planning is based on a 4 to 8 week subcutaneous course at 500 mcg daily, which works out to 3.5 mg per week.

Peptide Vials (KPV, 10 mg vial):

• Four weeks totals 14 mg and calls for 2 vials; eight weeks totals 28 mg and calls for 3 vials; a 12 week chronic IBD course totals 42 mg and calls for 5 vials. An eight week oral course at 1000 mcg daily totals 56 mg and calls for 6 vials.

Insulin Syringes (U-100):

• Per week on the once daily subcutaneous schedule: 7 syringes (U-100, 30 or 50 unit markings preferred at these volumes).
• Four weeks: 28 syringes. Eight weeks: 56 syringes. A twice daily block doubles both figures.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials, more than a full 12 week course.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site.
• Eight weeks at one injection daily: 112 swabs, so two 100 count boxes cover the course.

Important Notes

Practical considerations for consistency and safety.

• Oral route preferred for gut conditions. The PepT1 transporter is upregulated in inflamed colon tissue, so inflamed gut absorbs more KPV than healthy gut. That is natural drug targeting with no engineered modification behind it.
• Subcutaneous route preferred for systemic targets: skin inflammation, joint inflammation, and post-procedure inflammation control. Oral KPV reaches gut tissue first, and systemic bioavailability is lower without a prodrug formulation.
• No melanotropic effects. KPV is the C-terminal fragment; the HFRW core at residues 6 to 9 responsible for skin darkening, appetite effects, and MC1R through MC5R activation is structurally absent, so no pigmentation changes occur.
• Cycling is about matching the evidence, not about tolerance. No tolerance develops, since a receptor independent mechanism leaves no receptor to desensitize, but 4 to 8 week blocks with 2 to 4 weeks off match the durations preclinical work actually tested; 12 weeks is the ceiling for chronic IBD. Topical KPV is a separate matter: passive transdermal delivery sits below the detection limit, and only iontophoresis with microneedle pretreatment reaches a 35-fold improvement, so topical products claiming meaningful skin penetration without those technologies deserve scrutiny.
• Contraindications and cautions: pregnancy or breastfeeding (no data), active malignancy (precautionary, with no direct evidence of harm), and concurrent biologics or corticosteroids (theoretical additive immunosuppression, since no drug-interaction studies exist). Stacking partners named in the master sheet are BPC-157, TB-500, and GHK-Cu, combined in the KLOW blend; the rationale is pharmacologically plausible, but no controlled study has evaluated the combination.
• Regulatory Note: KPV has been classified FDA Category 2 since 2023 to 2024 and cannot be legally compounded under 503A or 503B. It is listed as a Substance with Safety Concerns, and the cited issue is the absence of human exposure data rather than demonstrated toxicity. Zero human clinical trials exist in any indication after more than 20 years of preclinical research. Supplied for research purposes only, not for human consumption. The master sheet does not record a WADA classification for this compound.

How This Works

KPV works through a three step receptor-independent mechanism. First, uptake: the SLC15A1 peptide transporter, PepT1, pulls KPV into cells with exceptionally high affinity, a Km of about 160 micromolar, among the lowest reported for human PepT1. PepT1 is normally expressed in the small intestine but is induced in inflamed colon tissue during IBD, creating a natural targeting system in which sicker tissue absorbs more peptide. Second, nuclear accumulation: histidine tagged KPV studies show the peptide migrates to the nucleus and becomes exclusively nuclear by 5 hours after treatment. Third, importin competition: the active component of NF-kB, p65 or RelA, cannot cross the nuclear membrane on its own and requires importin alpha 3 as a shuttle, and KPV binds the same armadillo repeat region of importin alpha 3 that p65 uses, blocking the shuttle. That binding model is computationally predicted using importin alpha 2 as a structural proxy; no crystal structure of the KPV and importin alpha 3 complex has been resolved. Downstream, p65 stays trapped in the cytoplasm bound to its inhibitor IkB-alpha, which also prevents IkB-alpha degradation, and the result is suppressed inflammatory gene transcription with reduced production of TNF-alpha, IL-6, IL-8, IL-12, IFN-gamma, and IL-1beta. KPV also suppresses MAPK signaling at nanomolar concentrations, though whether that is direct or secondary to NF-kB blockade is unresolved. The mechanism sits downstream of IKK activation and upstream of gene transcription, at a bottleneck no approved drug currently targets.

Benefits & Side Effects

Observations from the published record.

• Intestinal inflammation carries the strongest evidence: DSS and TNBS colitis mouse models show reduced disease activity scores, preserved colon length, and suppressed mucosal cytokine expression, with local action via PepT1 concentrating the effect at the disease site without requiring systemic absorption.
• The 2024 proKPV prodrug (Science Advances) is a ROS-responsive self-immolative conjugate that achieved 3.8-fold greater colonic accumulation and therapeutic efficacy at 20-fold lower doses than free KPV, and it also accumulated in inflamed lungs, suggesting broader oxidative stress responsive delivery.
• Skin and dermatology: KPV suppresses NF-kB in keratinocytes and endothelial cells comparably to full length alpha-MSH without skin darkening, and induces hapten specific tolerance in contact dermatitis models. The 2025 Sung study found 50 mcg/mL restored cell viability in PM10 exposed keratinocytes by blocking caspase-1 and IL-1beta.
• Dual antimicrobial action: picomolar activity against S. aureus and C. albicans via cAMP elevation in the pathogen rather than the host, without impairing neutrophil killing. This is the opposite of corticosteroids, which reduce inflammation while increasing infection risk.
• Other organ systems are thinner: a single neuroinflammation study (Schaible 2013, controlled cortical impact model) reported roughly 24% smaller secondary lesion volume from one IP injection 30 minutes post-injury, never independently replicated; airway work shows NF-kB suppression in human bronchial epithelial cells through the same importin alpha 3 mechanism, though eosinophil reduction in asthma and ARDS models came from full alpha-MSH rather than KPV alone; and 2024 cardiovascular data on KPV-rapamycin nanoparticles inhibiting vascular calcification remain early.
• Side effects and limits: no LD50 has been identified in rodents up to 100 mg/kg, and 4 to 12 week repeated dosing studies in animals showed minimal adverse effects, but zero human adverse event data has been published. What is not shown also matters: no human clinical efficacy or safety data, a computational rather than crystallographic importin alpha 3 binding model, poorly characterized MAPK specificity, systemic data largely extrapolated from full alpha-MSH, and mast cell stabilization claims that lack controlled dose-response studies measuring tryptase, histamine, or PGD2.

Lifestyle Factors

Complementary strategies for best outcomes.

• Identify the inflammation type first. KPV blocks the NF-kB node, so it acts on inflammatory cascades and not on mechanical pain, autoimmune antibody production, or structural damage; pairing it to the right problem is what makes it work.
• For gut applications: adequate fiber provides substrate for short-chain fatty acid production, reduced alcohol and ultra-processed food intake lowers the irritant load, and correcting sleep deficits removes an amplifier of gut immune dysregulation.
• For skin applications: minimize compounding inflammatory triggers such as UV exposure without SPF, harsh actives, and occlusive comedogenic products.
• Stack with repair, not against it. KPV is the firefighter, BPC-157 is the contractor, and TB-500 is the project manager; removing the fire without rebuilding leaves a damaged structure. Sleep and stress management lower baseline NF-kB activation, which amplifies what KPV is already doing pharmacologically.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Luger TA, Brzoska T. Alpha-MSH related peptides: anti-inflammatory and immunomodulating drugs (Ann Rheum Dis, 2007).
2. Getting SJ et al. Dissection of anti-inflammatory effect of core and C-terminal (KPV) alpha-MSH peptides (J Pharmacol Exp Ther, 2003).
3. Dalmasso G et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation (Gastroenterology, 2008).
4. Fagerlund R et al. NF-kB nuclear import via importin alpha 3 and importin alpha 4 (J Biol Chem, 2005).
5. Zhao Y et al. proKPV prodrug: inflammation-triggered self-immolative oral delivery (Sci Adv, 2024).
6. Schaible EV et al. KPV attenuates traumatic brain injury (Front Cell Neurosci, 2013).